Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer--experience from a prematurely closed phase II study

Lung Cancer. 2004 Jul;45(1):131-2. doi: 10.1016/j.lungcan.2004.01.008.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Camptothecin / administration & dosage
  • Camptothecin / adverse effects
  • Camptothecin / analogs & derivatives*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Docetaxel
  • Drug Administration Schedule
  • Female
  • Humans
  • Irinotecan
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / pathology
  • Male
  • Middle Aged
  • Survival Analysis
  • Taxoids / administration & dosage
  • Taxoids / adverse effects

Substances

  • Taxoids
  • Docetaxel
  • Irinotecan
  • Camptothecin